GSK’s failed cardiovascular drug losmapimod looks like it might get a new lease of life after being picked up by biotech Fulcrum Therapeutics, who want to repurpose the drug to treat the ra
The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies' pipelines as they tighten their focus on the projects with the most chance of a
GlaxoSmithKline is searching for a new chairman after Sir Philip Hampton announced he is to step down in the wake of the company’s split into two businesses.